554 related articles for article (PubMed ID: 23891770)
21. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
22. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
23. Anti-angiogenic quassinoid-rich fraction from Eurycoma longifolia modulates endothelial cell function.
Al-Salahi OS; Kit-Lam C; Majid AM; Al-Suede FS; Mohammed Saghir SA; Abdullah WZ; Ahamed MB; Yusoff NM
Microvasc Res; 2013 Nov; 90():30-9. PubMed ID: 23899415
[TBL] [Abstract][Full Text] [Related]
24. Development of collateral vessels: A new paradigm in CAM angiogenesis model.
Gatne DP; Mungekar S; Addepalli V; Mohanraj K; Ghone SA; Rege NN
Microvasc Res; 2016 Jan; 103():11-3. PubMed ID: 26390964
[TBL] [Abstract][Full Text] [Related]
25. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis.
Thapa D; Lee JS; Heo SW; Lee YR; Kang KW; Kwak MK; Choi HG; Kim JA
Eur J Pharmacol; 2011 Jan; 650(1):64-71. PubMed ID: 20950604
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
27. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
28. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
29. In vivo angiogenic activity of enamel matrix derivative.
Kauvar AS; Thoma DS; Carnes DL; Cochran DL
J Periodontol; 2010 Aug; 81(8):1196-201. PubMed ID: 20370422
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
[TBL] [Abstract][Full Text] [Related]
31. A quantitative angiogenesis model for efficacy testing of chemopreventive agents.
Sharma S; Ghoddoussi M; Gao P; Kelloff GJ; Steele VE; Kopelovich L
Anticancer Res; 2001; 21(6A):3829-37. PubMed ID: 11911254
[TBL] [Abstract][Full Text] [Related]
32. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
[TBL] [Abstract][Full Text] [Related]
33. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
34. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
35. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
36. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis inhibition by the maleimide-based small molecule GNX-686.
Nowak-Sliwinska P; Storto M; Cataudella T; Ballini JP; Gatz R; Giorgio M; van den Bergh H; Plyte S; Wagnières G
Microvasc Res; 2012 Mar; 83(2):105-10. PubMed ID: 22056402
[TBL] [Abstract][Full Text] [Related]
38. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
39. Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1.
Huang S; Yang N; Liu Y; Gao J; Huang T; Hu L; Zhao J; Li Y; Li C; Zhang X
Int J Mol Med; 2012 Dec; 30(6):1410-6. PubMed ID: 23026853
[TBL] [Abstract][Full Text] [Related]
40. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents.
Tufan AC; Satiroglu-Tufan NL
Curr Cancer Drug Targets; 2005 Jun; 5(4):249-66. PubMed ID: 15975046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
